Skip to main content

Cytek Biosciences, Inc. (CTKB)

NASDAQ: CTKB · IEX Real-Time Price · USD
23.56 -1.16 (-4.69%)
Sep 22, 2021 12:19 PM EDT - Market open
Market Cap3.13B
Revenue (ttm)99.12M
Net Income (ttm)20.35M
Shares Out132.99M
EPS (ttm)0.15
PE Ratio153.96
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume117,859
Open24.63
Previous Close24.72
Day's Range23.51 - 24.95
52-Week Range17.40 - 28.70
Betan/a
AnalystsBuy
Price Target27.00 (+14.6%)
Est. Earnings DateNov 2, 2021

About CTKB

Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full ...

IndustryMedical Devices
IPO DateJul 23, 2021
CEOWenbin Jiang, Ph.D.
Employees429
Stock ExchangeNASDAQ
Ticker SymbolCTKB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 14.60% from the latest price.

Price Target
$27.00
(14.60% upside)
Analyst Consensus: Buy

News

Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th A...

2 weeks ago - GlobeNewsWire

Cytek Biosciences Reports Second Quarter 2021 Financial Results

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021.

2 weeks ago - GlobeNewsWire

Cytek Biosciences Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwrite...

1 month ago - GlobeNewsWire

Cytek Biosciences Announces Closing of Its Initial Public Offering

FREMONT, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the closing of its ...

1 month ago - GlobeNewsWire

Cytek Biosciences Announces Pricing of Its Initial Public Offering

FREMONT, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis...

1 month ago - GlobeNewswire

Cytek Biosciences IPO Registration Document (S-1)

Cytek Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC